AbD Serotec Enters New Growth Area
(Thomson Reuters ONE) -
MorphoSys AG / AbD Serotec Enters New Growth Area processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Recombinant Anti-Idiotype Antibodies as Important Research and Drug Development
Tools
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
research and diagnostic antibody unit AbD Serotec is active in a new growth
area. AbD Serotec is increasingly providing anti-idiotype antibodies against
existing antibody drugs and drug candidates to accompany their preclinical and
clinical development. AbD Serotec already provides anti-idiotype antibodies to
several international pharmaceutical and biotechnology companies. Additionally,
anti-idiotype antibodies produced by AbD Serotec are being used in-house to
support MorphoSys's proprietary development programs in cancer and inflammatory
diseases.
The growing number of therapeutic antibodies in clinical development is driving
the demand for tools to monitor their concentration and behavior in patients,
including critical parameters such as pharmacokinetics and immunogenicity. Since
the majority of antibody-based drug candidates in clinical trials today is fully
human, the detection tools must differentiate between the drug and other
antibodies present in patient serum or plasma samples. HuCAL-based anti-idiotype
antibodies are ideal tools to detect the respective drug candidate with very
high sensitivity. With its fully recombinant HuCAL technology, AbD Serotec can
provide these tools quickly, allowing their customers to develop assays for
non-clinical and clinical samples in a very short time frame. The HuCAL platform
delivers fully human antibodies, a key factor for immunogenicity assays. At the
same time, the antibodies have a high affinity for their targets, which is a
prerequisite to reach the necessary sensitivity in a final assay.
"We see tools supporting preclinical research and clinical trials as a real
growth opportunity, in which we can deliver solutions with our cutting-edge
antibody technology", commented Dieter Feger, Head of AbD Serotec. "The use of
recombinant technology is a major advantage that positions us well in this
growing market".
"Anti-idiotype antibodies represent an important synergy between our therapeutic
and non-therapeutic business units", commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. "AbD Serotec now broadly supports our
proprietary development programs, providing high quality analytical tools with
excellent sensitivity for our pre-clinical and clinical work".
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1416430]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release: http://hugin.info/130295/R/1416430/367021.pdf
Unternehmensinformation / Kurzprofil:
![Draka Holding N.V.: Trading Update[1]](/modules/PresseInfo/thump/fp_bwk.gif "Draka Holding N.V.: Trading Update[1]")
Datum: 18.05.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 21019
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec Enters New Growth Area"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
